HC Wainwright Estimates Immunocore FY2029 Earnings

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Immunocore in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $7.53 per share for the year. HC Wainwright currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm had revenue of $80.25 million for the quarter, compared to analysts' expectations of $78.94 million. During the same period in the prior year, the firm earned ($0.59) earnings per share. The company's quarterly revenue was up 23.7% compared to the same quarter last year.

A number of other equities analysts have also commented on IMCR. Mizuho lowered Immunocore from an "outperform" rating to a "neutral" rating and reduced their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Guggenheim downgraded shares of Immunocore from a "buy" rating to a "neutral" rating in a research report on Monday, October 7th. UBS Group began coverage on shares of Immunocore in a research note on Thursday, October 24th. They issued a "sell" rating and a $24.00 target price for the company. Morgan Stanley reiterated an "equal weight" rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Finally, Needham & Company LLC restated a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a research report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $65.64.

Immunocore Price Performance

NASDAQ IMCR traded up $0.27 during trading hours on Tuesday, reaching $32.88. 185,266 shares of the company's stock were exchanged, compared to its average volume of 253,854. The firm has a fifty day moving average of $30.54 and a 200-day moving average of $33.21. Immunocore has a one year low of $27.69 and a one year high of $76.98. The stock has a market cap of $1.65 billion, a PE ratio of -34.61 and a beta of 0.76. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP grew its holdings in Immunocore by 10.5% during the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock valued at $219,430,000 after purchasing an additional 668,382 shares during the period. Primecap Management Co. CA increased its position in shares of Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company's stock valued at $76,954,000 after buying an additional 520,950 shares in the last quarter. Millennium Management LLC raised its stake in Immunocore by 124.4% during the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company's stock worth $20,366,000 after buying an additional 333,167 shares during the period. Two Sigma Advisers LP lifted its holdings in Immunocore by 65.6% during the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company's stock worth $23,587,000 after acquiring an additional 300,200 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock valued at $17,007,000 after purchasing an additional 109,206 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.